AzTrials
AzTrials

Coronary Artery DiseaseHYPNOCABGNCT07316868

Neuroprotective Effect of Mild Hypothermia Versus Normothermia During Cardiopulmonary Bypass of Coronary Artery Surgery

A study testing Normothermic cardiopulmonary bypass and Hypothermic cardiopulmonary bypass in people with Coronary Artery Disease and Brain Injury, run by Turku University Hospital at 1 site in Finland.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

In high-income countries, coronary artery bypass grafting (CABG) remains a common procedure, with approximately 36.7 operations per 100,000 inhabitants annually, corresponding to about 136,000 procedures in the European Union. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coronary Artery Disease, Brain Injury
What is being tested?
Normothermic cardiopulmonary bypass and Hypothermic cardiopulmonary bypass
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
160 participants
Where
1 siteFinland
Study dates
1 Jan 2026to 31 Dec 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed consent obtained
  • Age of >18 years
  • Undergoing elective or subacute coronary artery bypass grafting

Who cannot join

  • An emergency case
  • A history of stroke
  • A history of intracranial bleeding
  • A history of transient ischemic attack (TIA)
  • A history of neurodegenerative diseases such as Alzheimer's, multiple sclerosis
  • The subject is known to have a clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the subject to participate in this clinical trial.
  • Presence of implants or foreign bodies which are not known to be MRI safe

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Timo Laitio, M.D., PhD contact

+358504731639

timo.laitio@varha.fi

Finland1 site
  • Turku University Hospital

    Turku, FIN-20521

    Timo Laitio, M.D., PhD, +358504731639, timo.laitio@varha.fi

    Timo Laitio, MD, PhD, +358504731639, timo.laitio@varha.fi

Other trials in Finland

About this study

Official title: Neuroprotective Effect of Mild Hypothermia as Compared With Normothermia During Cardiopulmonary Bypass of Coronary Artery Bypass Grafting - A Single-center Randomized Controlled Trial

In high-income countries, coronary artery bypass grafting (CABG) remains a common procedure, with approximately 36.7 operations per 100,000 inhabitants annually, corresponding to about 136,000 procedures in the European Union. This highlights the substantial healthcare burden and the need to optimize surgical outcomes. Cardiopulmonary bypass (CPB) is a fundamental component of cardiac surgery, ensuring extracorporeal perfusion of vital organs.

Hypothermic CPB has historically been widely used for organ protection due to its presumed neuroprotective mechanisms. However, evidence demonstrating its superiority over normothermic CPB remains inconclusive. In its 2024 guidelines, the European Association for Cardio-Thoracic Surgery recommends considering normothermia (≥35 °C) to reduce postoperative neurocognitive dysfunction (Class II, Level A). This recommendation is primarily based on two meta-analyses, but the underlying studies show methodological heterogeneity, outdated practices, and limited applicability to contemporary cardiac surgery. Importantly, the guidelines acknowledge the need for large randomized controlled trials to define optimal target temperature management (TTM) during CPB.

Read more

Previous diffusion-weighted MRI studies have demonstrated silent ischemic brain lesions in approximately 30% of CABG patients, with postoperative neurocognitive decline occurring in a similar proportion. However, no significant differences have been shown between normothermic and hypothermic CPB. Diffusion tensor imaging (DTI) extends conventional diffusion imaging by enabling detailed assessment of white matter microstructure and tractography. Fractional anisotropy (FA), a key DTI metric, has demonstrated prognostic value in various neurological conditions but has not yet been applied in CABG patients.

Blood-based biomarkers, including glial fibrillary acidic protein, neurofilament light chain, neuron-specific enolase, and total tau, offer complementary insights into brain injury but have not been studied in combination with DTI in this population.

This study will compare mild hypothermic (33-34 °C) and normothermic (36.5 °C) CPB to evaluate their neuroprotective effects using advanced MRI techniques and blood-based biomarkers. The primary aim is to determine whether mild hypothermia provides superior neuroprotection following CABG. Secondary objectives include assessing white matter injury evolution, global ischemic burden, associations with biomarkers and neurocognitive decline, and developing integrated prognostic models to improve outcomes in CABG patients.

Read the detailed description

In high-income countries, 36.7 coronary artery bypass grafting (CABG) procedures are performed per 100,000 population each year, translating to approximately 136,000 procedures in the European Union, and thereby underscoring the significant healthcare burden and importance of optimizing surgical outcomes. During cardiac surgery, cardiopulmonary bypass (CPB), a cornerstone of cardiac surgery, ensures extracorporeal perfusion to critical organs.

Historically, hypothermic CPB has been employed in the majority of cardiac operations and remains one of the most common methods for organ protection in routine cardiac surgery. The biological rationale for hypothermia is grounded in its multiple mechanisms of neuroprotection. Despite these findings, the superiority of hypothermic CPB over normothermic CPB in terms of neuroprotection remains uncertain.

In its 2024 guidelines, the European Association for Cardio-Thoracic Surgery recommends considering normothermia (defined as temperatures ≥ 35°C) to reduce the risk of postoperative neurocognitive dysfunction (Class II, Level A recommendation). Hypothermia, in this context, is defined as a core temperature below 35°C. The recommendation is based on two recent meta-analyses: Abbasciano et al. 2022 and Linassi et al. 2022. However, the 2024 recommendation is underpinned by evidence that remains limited in quality and relevance. The key studies included in these meta-analyses exhibit methodological inconsistencies and rely on outdated definitions and clinical practices, thereby limiting the generalizability and applicability of the findings to current cardiac surgical and anesthetic practice. Notably, the recommendation itself acknowledges the need for large randomized controlled trials to determine the optimal target temperature management (TTM) during cardiopulmonary bypass (CPB).

Previous studies using diffusion-weighted imaging (DWI) in magnetic resonance imaging (MRI) have revealed silent ischemic brain lesions, predominantly deep white matter lesions, in approximately 30% of patients following CABG. Furthermore, postoperative neurocognitive decline occurs in an average of 30.2% of CABG patients. However, earlier DWI and neurocognitive studies have not demonstrated statistically significant differences between normothermic and hypothermic CPB.

Diffusion tensor imaging (DTI) extends the capabilities of DWI and offers several advantages. Unlike DWI, which measures diffusion magnitude, DTI provides detailed quantitative insights into white matter architecture and allows for visualization and quantification of white matter tracts through tractography. Fractional anisotropy (FA), a key DTI parameter, quantifies the magnitude and directionality of water diffusion within white matter tracts. FA has shown independent prognostic value for neurological outcomes in patients with traumatic brain injury, subarachnoid hemorrhage, or cardiac arrest. Despite its potential, DTI has not yet been applied to CABG patients. This technique could significantly enhance our understanding of white matter microintegrity evolution and overall injury burden following CABG, insights necessary for optimizing TTM during CPB.

In addition to brain imaging with DTI, blood-based biomarkers such as glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), neuron-specific enolase (NSE), and total tau (T-tau) provide complementary tools for monitoring brain injury progression and improving prognostication of long-term neurological outcomes. Each biomarker are expressed in different cellular origins and exhibit distinct characteristics and temporal dynamics, potentially offering unique insights into the extent of brain injury post-CABG. However, their ability to independently or synergistically measure white and gray matter injury in combination with DTI parameters remains unexplored in CABG patients.

To optimize TTM during CPB, this study will investigate the neuroprotective effects of hypothermic (33-34 °C) and normothermic (36.5 °C) CPB by evaluating their impact on white matter injury, cerebral perfusion, and whole-brain neural networks using advanced MRI techniques.

The primary aim of this study is to evaluate whether mild hypothermic CPB offers superior neuroprotection compared to normothermic CPB. This will be assessed using brain DTI and blood-based biomarkers following CABG. Secondary objectives include evaluating the evolution of white matter architecture, the extent of global ischemic injury to white matter microintegrity, and the association between these factors, postoperative blood-based biomarker levels, and neurocognitive decline. In addition, an objective is to develop innovative and highly precise prognostic models by integrating advanced brain imaging technologies with comprehensive biomarker analysis. Ultimately, the overarching goal is to identify factors that can improve the treatment outcomes for patients undergoing CABG.

Being tested
Normothermic cardiopulmonary bypass, Hypothermic cardiopulmonary bypass
Keywords
hypothermia, normothermia, cardiopulmonary bypass, coronary artery bypass grafting, diffusion tensor imaging, neuroprotection, biomarkers
Medical subject headings
Coronary Artery Disease, Brain Injuries, Hypothermia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Normothermic cardiopulmonary bypassProcedure or surgery

    Also called 36.5 ± 0.2°C

    normothermic cardiopulmonary bypass with nasopharyngeal temperature of 36.5 ± 0.2°C

  • Hypothermic cardiopulmonary bypassProcedure or surgery

    Also called 33 ± 0.2°C

    mild hypothermic cardiopulmonary bypass with nasopharyngeal temperature of 33 ± 0.2°C

Study groups in NCT07316868
Study groupRoleWhat they receive
Intervention groupActive comparatorIntervention group: normothermic cardiopulmonary bypass with nasopharyngeal temperature of 36.5 ± 0.2°C
Receives: Procedure: Normothermic cardiopulmonary bypass
Control groupActive comparatorControl group: mild hypothermic cardiopulmonary bypass with nasopharyngeal temperature of 33 ± 0.2°C
Receives: Procedure: Hypothermic cardiopulmonary bypass

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Global fractional anisotropy of brain white matter of diffusion tensor imaging (DTI)

    Fractional anisotropy measures white matter microintegrity. It is assessed with brain magnetic resonance diffusion tenson imaging (DTI)

    Measured: Postoperative Day 6 +/- 1 day

Secondary outcomes (17)
  1. Change in hippocampal volume in milliliters (ml) from preoperative day 4 (+/- 3 days) to postoperative day 6 (+/-1 day) between the control and the intervention group

    The volume of hippocampus will be measured with voxel-based morphometry of magnetic resonance imaging at preoperative day 4 +/- 3 days and at postoperative day 6 +/- 1day.

    Measured: Change of hippocampal volume between preoperative day 4 +/- 3 days and postoperative day 6 +/- 1day

  2. Number of participants with treatment related adverse events as assessed by CTCAE v 4.0

    Measured: From enrollment to the end of follow-up at 1 year

  3. Change in hippocampal ischemic injury from preoperative day 4 +/- 3 days to postoperative day 6 +/- 1 day between the control group and the intervention group.

    The ischemic injury in the hippocampus will be measured with magnetic resonance diffusion tensor imaging

    Measured: The change of hippocampal ischemic injury from the preoperative day 4 +/-3 days to postoperative day 6 +/- 1 day

  4. Change in ischemic injury of basal ganglia from preoperative day 4 +/- 3 days to postoperative day 6+/- 1 day between the control group and the intervention group

    The ischemic injury in basal ganglia will be measured with the magnetic resonance diffusion tensor imaging

    Measured: The change of ischemic injury in basal ganglia from the ppreoperative day 4 +/- 3 days to postoperative day 6 +/- 1 day

  5. Change of global white matter injury as assessed with diffusion tensor imaging between the control group and the intervention group from preoperative day 4 +/- 3 days to postoperative day 6 +/- 1 day and to 3 months +/- 7 days

    The global (i.e. the whole brain) ischemic white matter injury will be measured with fractional anisotropy and with radial, axial and mean diffusivity of the magnetic resonance diffusion tensor imaging. These parameters are always measured simultaneously and cannot be separated.

    Measured: Change of global ischemic white matter injury from preoperative day 4 +/- 3 to postoperative day 6 +/-1 day and to 3 months +/- 7 days

  6. Change of global gray matter injury between the control group and the intervention group from preoperative day 4 +/- 3 days to postoperative day 6 +/- 1 day and to 3 months +/- 7 days

    The global (i.e. the whole brain) gray matter injury will be measured with mean diffusivity of diffusion tensor imaging

    Measured: Change of global gray matter injury from preoperative day 4 +/- 3 days to postoperative day 6 +/- 1 day and to 3 months +/- 7 days after operation

  7. Difference of blood-based neuron specific enolase (NSE) between the control group and the intervention group

    NSE is analyzed from a blood sample

    Measured: NSE is analysed immediately prior to anesthesia induction and at postoperative 24, 48 and at 72 hours

  8. Difference of blood-based neurofilament light chain (NfL) between the control group and the intervention group

    NfL is analyzed from a blood sample

    Measured: NfL is analyzed immediately prior to anesthesia induction and at postoperative 24, 48 and at 72 hours

  9. Difference of blood-based glial fibrillary acidic protein (GFAP) between the control group and the intervention group

    GFAP is analyzed from a blood sample

    Measured: GFAP is analyzed immediately prior to anesthesia induction and at postoperative 24, 48 and at 72 hours

  10. Difference of blood-based total tau between the control group and the intervention group

    total tau is analyzed from a blood sample

    Measured: total tau is analyzed immediately prior to anesthesia induction and at postoperative 24, 48 and at 72 hours

  11. Difference of neurocognitive outcomes between the control group and the intervention group as assessed with the Cambridge Neuropsychological Test Automated Battery (CANTAB)

    Measured: CANTAB will be assessed at preoperative day 2 +/- 1 day and postoperatively at 3 and at 12 months

  12. Difference of intraoperative Near-Infrared Spectroscopy NIRS values between the control and the intervention group during .

    Measured: NIRS will be measured intraoperatively

  13. Difference in the need for vasoactive medication between the control group and the intervention group.

    Vasoactive medication includes norepinephrine, epinephrine, vasopressin, levosimendan and nitroglycerin

    Measured: 96 hours after start of anesthesia induction

  14. The need for antipyretic medication between the contorl group and the interventin group

    Measured: 96 hours after start of anesthesia induction

  15. Blood lactate levels between the control group and the intervention group

    Measured: Lactate will be measured intraoperatively at 1-hour intervals and at intervals of 2 to 6 hours from the start to the end of postoperative intensive care

  16. Difference of a quantity of blood products and hemostatic agents between the control and the intervention group

    Measured: 96 hours after start of anesthesia induction

  17. Difference of the length of intensive care unit stay between the control group and the intervention group

    Measured: 96 hours after start of anesthesia induction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2026
  2. Study start1 Jan 2026 (estimated)
  3. Primary completion31 Dec 2029 (estimated)
  4. Study completion31 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a single-blinded randomized clinical trial
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
160 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07316868
Sponsor's protocol ID
VARHA/4272/13.02.02/2025
Acronym
HYPNOCABG
Status last verified
Dec 2025
First submitted
24 Nov 2025
Last updated
5 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Primary endpoint

Questions about this trial

What is this clinical trial studying?

A study testing Normothermic cardiopulmonary bypass and Hypothermic cardiopulmonary bypass in people with Coronary Artery Disease and Brain Injury, run by Turku University Hospital at 1 site in Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Timo Laitio, M.D., PhD (+358504731639, timo.laitio@varha.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Global fractional anisotropy of brain white matter of diffusion tensor imaging (DTI) (time frame: Postoperative Day 6 +/- 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in